Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7S8H

Structure of Lassa virus glycoprotein bound to Fab 18.5C and Fab 36.1F

Summary for 7S8H
Entry DOI10.2210/pdb7s8h/pdb
DescriptorGlycoprotein G1, alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... (12 entities in total)
Functional Keywordslassa virus, pre-fusion glycoprotein, fab fragment, antibody-mediated neutralization, viral protein, viral protein-immune system complex, viral protein/immune system
Biological sourceLassa virus
More
Total number of polymer chains6
Total formula weight143631.14
Authors
Hastie, K.M.,Enriquez, A.S. (deposition date: 2021-09-17, release date: 2022-06-01, Last modification date: 2024-10-30)
Primary citationEnriquez, A.S.,Buck, T.K.,Li, H.,Norris, M.J.,Moon-Walker, A.,Zandonatti, M.A.,Harkins, S.S.,Robinson, J.E.,Branco, L.M.,Garry, R.F.,Saphire, E.O.,Hastie, K.M.
Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies.
Cell Rep, 39:110841-110841, 2022
Cited by
PubMed Abstract: Lassa virus (LASV) is the etiologic agent of Lassa Fever, a hemorrhagic disease that is endemic to West Africa. During LASV infection, LASV glycoprotein (GP) engages with multiple host receptors for cell entry. Neutralizing antibodies against GP are rare and principally target quaternary epitopes displayed only on the metastable, pre-fusion conformation of GP. Currently, the structural features of the neutralizing GPC-A antibody competition group are understudied. Structures of two GPC-A antibodies presented here demonstrate that they bind the side of the pre-fusion GP trimer, bridging the GP1 and GP2 subunits. Complementary biochemical analyses indicate that antibody 25.10C, which is broadly specific, neutralizes by inhibiting binding of the endosomal receptor LAMP1 and also by blocking membrane fusion. The other GPC-A antibody, 36.1F, which is lineage-specific, prevents LAMP1 association only. These data illuminate a site of vulnerability on LASV GP and will guide efforts to elicit broadly reactive therapeutics and vaccines.
PubMed: 35613585
DOI: 10.1016/j.celrep.2022.110841
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.7 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon